In the lead-up to rare disease day, centogene expands observational study to advance the genetic understanding of frontotemporal dementia (ftd)

Cambridge, mass. and rostock, germany and berlin, feb. 21, 2023 (globe newswire) -- centogene n.v. (nasdaq: cntg), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has extended and expanded the observational efront study to advance the genetic understanding of frontotemporal dementia (ftd).
CNTG Ratings Summary
CNTG Quant Ranking